AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021)
AbCellera Biologics (ABCL) reported Receivables - Other of $62.1 million for Q2 2021, down 67.84% quarter-over-quarter from $193.1 million in Q1 2021.
AbCellera Biologics (ABCL) Receivables - Other (2020 - 2021) Analysis & Trends
AbCellera Biologics has reported Receivables - Other for 2 years, with the latest figure at $62.1 million in Q2 2021.
- For the quarter ending Q2 2021, Receivables - Other changed N/A year-over-year to $62.1 million; the trailing twelve-month figure through Jun 2021 stood at $62.1 million (changed N/A YoY), and the FY2020 full-year result was $212.3 million, changed N/A from the prior year.
- Receivables - Other for Q2 2021 stood at $62.1 million, down from $193.1 million in the prior quarter.
- The five-year high for Receivables - Other was $212.3 million in Q4 2020, with the low at $62.1 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | AbCellera Biologics | 1.55 Bn | 1.44 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 62.09 Mn |
| Jun 30, 2021 | 62.09 Mn |
| Mar 31, 2021 | 193.07 Mn |
| Mar 31, 2021 | 193.07 Mn |
| Dec 31, 2020 | 212.34 Mn |
| Dec 31, 2020 | 212.34 Mn |